I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

And it’s never a bad time to re-read some of the team’s excellent, award-winning coverage on the company: Last week, key ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its blockbuster weight loss drugs Wegovy and Ozempic. Lars Fruergaard Jørgensen ...

Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images U.S.-listed shares of Novo Nordisk (NVO) declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard ...

Novo Nordisk CEO Lars Fruergaard Jørgensen to step down amid board and market pressure. Despite leadership changes, the company maintains its strategy. Ready to turn the market’s comeback into ...

Under Jorgensen's leadership, Novo Nordisk became a world leader in the lucrative weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments. Sign up here. "The changes ...

Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an oral version of its blockbuster weight loss drug Wegovy. The Danish drugmaker – which has its U.S ...